Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences (Nasdaq: RNA) announced participation in several major healthcare conferences, showcasing their innovative RNA therapeutic approach through Antibody Oligonucleotide Conjugates (AOCs™). Key events include a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, a corporate panel at the Cowen 42nd Annual Health Care Conference on March 7, and another fireside chat at the Needham 21st Annual Healthcare Conference on April 12. Avidity aims to advance their clinical pipeline with AOC 1001 for myotonic dystrophy and additional therapies targeting muscular diseases.
- None.
- None.
LA JOLLA, Calif., Feb. 11, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:
SVB Leerink 11th Annual Global Healthcare Conference
Moderated Fireside Chat
February 18th – 2:20pm ET
Cowen 42nd Annual Health Care Conference
Corporate Panel Discussion: Orphan Neuro and Neuromuscular – Sarah Boyce, CEO
March 7th, 2022 – 9:10am ET
Needham 21st Annual Healthcare Conference
Moderated Fireside Chat
April 12, 2022
Live webcasts of each event, up to date event details and an archived replay of the webcasts following each event, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCsTM). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity is on track to have three programs in clinical development by the end of 2022. The company's lead product candidate, AOC 1001, is designed to treat patients with myotonic dystrophy type 1 (DM1). AOC 1001 has commenced clinical testing with the ongoing Phase 1/2 MARINATM trial in adults with DM1. The next programs in the company's advancing and expanding pipeline are AOC 1044, the lead of three programs for the treatment of DMD, and AOC 1020, designed to treat people living with FSHD. Avidity anticipates both programs will enter the clinic by the end of 2022. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.
Company Contact:
Kath Gallagher
kath.gallagher@aviditybio.com
(858) 401-7900
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301480830.html
SOURCE Avidity Biosciences, Inc.
FAQ
What is Avidity Biosciences' stock symbol?
When will Avidity Biosciences participate in the SVB Leerink Healthcare Conference?
What is the focus of Avidity's upcoming panel discussion at the Cowen Conference?
What is the clinical candidate AOC 1001 developed by Avidity?
When is Avidity's next healthcare conference participation scheduled?
